Scarica l'app Stockscreener
10.06
2.33%
-0.24
Precedente Chiudi:
$10.30
Aprire:
$10
Volume 24 ore:
7,532
Relative Volume:
0.29
Capitalizzazione di mercato:
$63.58M
Reddito:
$28.83M
Utile/perdita netta:
$-13.34M
Rapporto P/E:
-6.6184
EPS:
-1.52
Flusso di cassa netto:
$-7.49M
1 W Prestazione:
-12.06%
1M Prestazione:
-12.90%
6M Prestazione:
+246.90%
1 anno Prestazione:
+287.67%
Intervallo 1D:
$9.99
$10.30
Intervallo di 1 settimana:
$9.99
$11.86
Portata 52W:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
Nome
Exicure Inc
Settore
Industria
Telefono
847-673-1700
Indirizzo
2430 N. HALSTED ST., CHICAGO, IL
Confronta XCUR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.79 | 372.90M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.00 | 215.29M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.87 | 149.00M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1641 | 340.19M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.3476 | 371.47M | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | Iniziato | BMO Capital Markets | Outperform |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
Exicure Inc Borsa (XCUR) Ultime notizie
Exicure Delays 10-Q Filing Amid Acquisition - TipRanks
(XCUR) Investment Analysis and Advice - news.stocktradersdaily.com
Exicure enters strategic convertible bond agreement By Investing.com - Investing.com Nigeria
Exicure Enters Convertible Bond Agreement with Subsidiary - TipRanks
Exicure enters strategic convertible bond agreement - Investing.com
Exicure concludes subject enrolment in trial of GPC-100 for multiple myeloma - Yahoo Finance
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant | XCUR Stock News - GuruFocus
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
Geode Capital Management LLC Purchases Shares of 12,645 Exicure, Inc. (NASDAQ:XCUR) - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement Payouts - TradingView
Why Exicure Inc. (XCUR) Soared on Monday - MSN
How To Trade (XCUR) - news.stocktradersdaily.com
10 Micro-, Small-Cap Companies Lead Monday’s Charge - Insider Monkey
Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener
Exicure appoints new independent accounting firm By Investing.com - Investing.com India
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study o - GuruFocus
Exicure appoints new independent accounting firm - Investing.com Australia
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace
How to Take Advantage of moves in (XCUR) - news.stocktradersdaily.com
Eli Lilly and Company (NYSE:LLY) and Exicure (NASDAQ:XCUR) Head to Head Analysis - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Growth in Short Interest - The AM Reporter
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Grows By 58.5% - Defense World
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks - Investing.com India
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks By Investing.com - Investing.com UK
Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com
Major Investment Alert: HiTron Systems Inc. Boosts Stake in Exicure! - TipRanks
HiTron Systems acquires $8.7 million in Exicure stock By Investing.com - Investing.com Canada
HiTron Systems acquires $8.7 million in Exicure stock - Investing.com
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Business Wire
Exicure Inc Reports $9.7 Million Net Loss for Fiscal Year 2024 A - GuruFocus
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference - Business Wire
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 24.2% - Defense World
Exicure, Inc. Reports Full Year 2024 Financial Results - BioSpace
EXICURE, INC. SEC 10-K Report - TradingView
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Exicure, Inc. Investors to Secure Counsel Before Important February 11 Deadline in Securities Class Action – XCUR - Business Wire
Pre-Market Momentum: Exicure (XCUR) Shares Rise After Key Approval - Stocks Telegraph
When (XCUR) Moves Investors should Listen - Stock Traders Daily
Exicure Gets Patent in Australia for Potential Cancer Treatment Combination -March 14, 2025 at 04:32 am EDT - Marketscreener.com
Exicure secures Australian patent for cancer treatment - Investing.com Australia
Exicure, Inc. Announces Issuance Of New Patent In Australia -March 13, 2025 at 05:39 pm EDT - Marketscreener.com
Exicure announces issuance of new patent in Australia - TipRanks
Exicure secures Australian patent for cancer treatment By Investing.com - Investing.com South Africa
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Business Wire
Exicure Inc Azioni (XCUR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):